Eris Lifesciences shareholding pattern

ERIS

1342.4

14.00 (1.05%)
Last updated on 20 Feb, 2026 | 15:53 IST
alert_iconwatchlist_icon
BUYSELL
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Eris Lifesciences Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

54.85%

Mutual Fund

18.26%

Insurance

1.25%

Foreign Institutional Investors

6.85%

Domestic Institutional Investors

0.81%

Retail

17.99%

Others

-0.01%

Total Promoters
MAR '25
54.85%
JUN '25
54.83%
SEP '25
54.85%
DEC '25
54.85%

Summary

For Year 2025-26, Eris Lifesciences reports the following shareholding: Total Promoters at 54.85%, Mutual Fund at 18.26%, Insurance at 1.25%, Foreign Institutional Investors at 6.85%, Domestic Institutional Investors at 0.81%, and Retail at 17.99%. This breakdown provides a quick snapshot of ownership distribution for Eris Lifesciences in 2025-26.

Eris Lifesciences FAQs

As of 02-2026, the promoter shareholding in Eris Lifesciences stands at 54.85% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Eris Lifesciences is 6.85% and 0.81% respectively.

The retail shareholding of the Eris Lifesciences is 17.99%.

Changes in shareholding patterns of Eris Lifesciences can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Eris Lifesciences are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost